Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?

Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?

Background: Cholangiocarcinoma (CCA) encompasses a heterogeneous group of malignant tumors with dismal prognosis and increasing incidence worldwide. Both late diagnosis due to the lack of early symptoms and the refractory nature of these tumors seriously compromise patients’ welfare and outcomes. Su...

Full description

Bibliographic Details
Main Authors: María Gutiérrez-Larrañaga, Elena González-López, Adriel Roa-Bautista, Pedro M. Rodrigues, Álvaro Díaz-González, Jesus M. Banales, Marcos López-Hoyos, Alvaro Santos-Laso, Javier Crespo
Format: Article
Language:English
Published: Karger Publishers 2021-09-01
Series:Liver Cancer
Subjects:
cholangiocarcinoma
therapy
prognosis
clinical trials
immune checkpoint inhibitors
Online Access:https://www.karger.com/Article/FullText/518104

Similar Items

Similar Items